secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001193805-26-000214
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus FY2025 net loss narrows to $65.8M; revenue falls 46% to $82M; CF program advances
--------------------------------------------------------------------------------

- Q4 net loss $29.1M ($1.03/shr) vs $30.0M loss prior year; FY net loss $65.8M ($2.40/shr) vs $80.9M.
- Revenue Q4 $7.2M, FY $82.0M, down $70.3M YoY due to lower CSL collaboration milestones and supply activity.
- Cash $232.8M at Dec 31, 2025; cash runway extended into Q2 2028.
- ARCT-032 (CF) third cohort (15 mg, 28 days) safe; 12-week Phase 2 study to start H1 2026.
- KOSTAIVE COVID-19 vaccine granted UK MHRA approval in Jan 2026; BARDA pandemic flu vaccine shows durable immune response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380526000214/0001193805-26-000214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380526000214/e665201_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-000214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer